An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.

@article{Aulakh2007AnUO,
  title={An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.},
  author={Gaganjot Kaur Aulakh and Rupinder Kaur Sodhi and Mohan Singh},
  journal={Life sciences},
  year={2007},
  volume={81 8},
  pages={615-39}
}
The renin-angiotensin-aldosterone-system (RAAS) is an important regulator of blood pressure and fluid-electrolyte homeostasis. RAAS has been implicated in pathogenesis of hypertension, congestive heart failure, and chronic renal failure. Aliskiren is the first non-peptide orally active renin inhibitor approved by FDA. Angiotensin Converting Enzyme (ACE) Inhibitors are associated with frequent side effects such as cough and angio-oedema. Recently, the role of ACE2 and neutral endopeptidase (NEP… CONTINUE READING